Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2017 Mar 22

PMID 28321395

Citations 7

Authors

Jesus M Cortes

Giovanni De Petris

Jose I Lopez

Affiliations

Soon will be listed here.

Abstract

Current sampling protocols of neoplasms along the digestive tract and in the urinary bladder have to be updated, as they do not respond to the necessities of modern personalized medicine. We show here that an adapted version of multisite tumor sampling (MSTS) is a sustainable model to overcome current deficiencies in digestive and bladder tumors when they are large enough so as to make unaffordable a total sampling. The new method is based on the divide-and-conquer algorithm and includes a slight modification of the MSTS, which proved to be useful very recently in clear cell renal cell carcinoma. This analysis confirms the usefulness of MSTS for detecting intratumor heterogeneity (ITH) in tumors arising in hollow viscera. However, MSTS does not seem to improve routine traditional sampling in detecting tumor budding, extramural venous invasion, and perineural invasion. We conclude that (1) MSTS is the best method for tumor sampling to detect ITH balancing high performance and sustainable cost, (2) MSTS must be adapted to tumor shape and tumor location for an optimal performance.

Citing Articles

Dynamic Assessment of Tissue and Plasma -Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs.

Ho H, Wang F, Chiang C, Tsai C, Chiu C, Chou T Int J Mol Sci. 2022; 23(19).

PMID: 36232650 PMC: 9569685. DOI: 10.3390/ijms231911353.

Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas.

Manini C, Lopez-Fernandez E, Lopez J Cancers (Basel). 2022; 14(14).

PMID: 35884442 PMC: 9322795. DOI: 10.3390/cancers14143381.

Intratumor graph neural network recovers hidden prognostic value of multi-biomarker spatial heterogeneity.

Qiu L, Kang D, Wang C, Guo W, Fu F, Wu Q Nat Commun. 2022; 13(1):4250.

PMID: 35869055 PMC: 9307796. DOI: 10.1038/s41467-022-31771-w.

Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases.

Prochazkova K, Ptakova N, Alaghehbandan R, Williamson S, Vanecek T, Vodicka J Cancers (Basel). 2021; 13(23).

PMID: 34885018 PMC: 8656868. DOI: 10.3390/cancers13235906.

PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.

Filipovic J, Bosic M, Cirovic S, Zivotic M, Dunderovic D, dordevic D Diagn Pathol. 2019; 14(1):120.

PMID: 31655611 PMC: 6815371. DOI: 10.1186/s13000-019-0901-6.

References

Waclaw B, Bozic I, Pittman M, Hruban R, Vogelstein B, Nowak M . A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature. 2015; 525(7568):261-4. PMC: 4782800. DOI: 10.1038/nature14971. View

Kobayashi K, Matsumoto H, Matsuyama H, Fujii N, Inoue R, Yamamoto Y . Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Oncol Rep. 2016; 36(5):2852-2860. DOI: 10.3892/or.2016.5061. View

Dou R, Nishihara R, Cao Y, Hamada T, Mima K, Masuda A . MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol Res. 2016; 4(11):927-935. PMC: 5115629. DOI: 10.1158/2326-6066.CIR-16-0112. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Eiro N, Pidal I, Fernandez-Garcia B, Junquera S, Lamelas M, del Casar J . Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One. 2013; 7(12):e52796. PMC: 3530508. DOI: 10.1371/journal.pone.0052796. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Carneiro F, Oliveira C, Suriano G, Seruca R . Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol. 2007; 61(1):25-30. DOI: 10.1136/jcp.2006.043679. View

Grigore A, Jolly M, Jia D, Farach-Carson M, Levine H . Tumor Budding: The Name is EMT. Partial EMT. J Clin Med. 2016; 5(5). PMC: 4882480. DOI: 10.3390/jcm5050051. View

Amiri M, Janssen F, Kunst A . The decline in stomach cancer mortality: exploration of future trends in seven European countries. Eur J Epidemiol. 2010; 26(1):23-8. PMC: 3018592. DOI: 10.1007/s10654-010-9522-9. View

10.

Jass J, OBrien J, Riddell R, Snover D . Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol. 2007; 129(1):13-23. DOI: 10.1309/6UHNC7MAD8KWNAWC. View

11.

Hudler P . Challenges of deciphering gastric cancer heterogeneity. World J Gastroenterol. 2015; 21(37):10510-27. PMC: 4588074. DOI: 10.3748/wjg.v21.i37.10510. View

12.

Koelzer V, Langer R, Zlobec I, Lugli A . Tumor budding in upper gastrointestinal carcinomas. Front Oncol. 2014; 4:216. PMC: 4132482. DOI: 10.3389/fonc.2014.00216. View

13.

Angulo J, Lopez J, Flores N, Toledo J . The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification. J Cancer Res Clin Oncol. 1993; 119(10):578-93. DOI: 10.1007/BF01372721. View

14.

Rogers A, Winter D, Heeney A, Gibbons D, Lugli A, Puppa G . Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016; 115(7):831-40. PMC: 5046217. DOI: 10.1038/bjc.2016.274. View

15.

Potter M, Newport E, Morten K . The Warburg effect: 80 years on. Biochem Soc Trans. 2016; 44(5):1499-1505. PMC: 5095922. DOI: 10.1042/BST20160094. View

16.

Lopez J, Cortes J . A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling. F1000Res. 2016; 5:1587. PMC: 4965694. DOI: 10.12688/f1000research.9091.2. View

17.

De la Fuente I . Elements of the cellular metabolic structure. Front Mol Biosci. 2015; 2:16. PMC: 4428431. DOI: 10.3389/fmolb.2015.00016. View

18.

Mayo E, Llanos A, Yi X, Duan S, Zhang L . Prognostic value of tumour deposit and perineural invasion status in colorectal cancer patients: a SEER-based population study. Histopathology. 2016; 69(2):230-8. DOI: 10.1111/his.12936. View

19.

Amin M, Srigley J, Grignon D, Reuter V, Humphrey P, Cohen M . Updated protocol for the examination of specimens from patients with carcinoma of the urinary bladder, ureter, and renal pelvis. Arch Pathol Lab Med. 2003; 127(10):1263-79. DOI: 10.5858/2003-127-1263-UPFTEO. View

20.

Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R . Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004; 45(3):257-66. DOI: 10.1016/j.eururo.2003.09.018. View